ARCHIVES

NCI Plans Trials of Burzynski’s ‘Antineoplaston’; JAMA Report Says No Antitumor Activity In Tests

This article is from The Cancer Letter archive.

Vol. 18 No. 23 | June 5, 1992

Download PDF Visit The Full Archive

Related Articles

Fragmin Cuts Risk Of VE By 50 Percent In Study

January 31, 2003

Amgen Halts Phase III Trial Of Ganitumab Plus Gemcitabine

August 31, 2012

Cancer Control Planning Conference Delayed To 1977

August 13, 1976

Cooperative Groups Cut In On $1 Million Head 7 Neck Projects

March 25, 1977

Taxotere Added To Regimen Improves Survival, Study Finds

July 29, 2005

New Treatment Projects Get Go-Ahead; Groups Competition To Be Increased, VA Studies Face Cut

November 4, 1977